title: [I. Docetaxel must be reconsidered in light of high cost-effectiveness in the treatment of prostate cancer].
authors.forename: Go
authors.initials: G
authors.lastname: Kimura
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003362:Cost-Benefit Analysis; D000077143:Docetaxel; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000191:economics; D043823:Taxoids / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel